Objective: Stroke is the second main cause of death worldwide. Recovery from a stroke differsfrom person to person. Melatonin is a neuroprotective agent with low adverse effects. Thelimitation of melatonin studies on human and other clinical bases made us keen to took up thisresearch work to explore its full potential as a neuroprotective agent. The purpose of thisresearch was to evaluate the effect of melatonin in stroke recovery inpatients.

Methods: This was a present prospective observational study carried out at the Department ofNeurology of tertiary care hospital over six months. Patient data were collected through historyinterview and from the case sheets. Continuous variables were presented as the minimum,maximum, median, mean, and standard error of the mean (SEM). Categorical variables werepresented as frequencies and percentages.

Results: A total of 80 patients were included in this study based on inclusion criteria. Asignificant difference was not found in the age and gender between the two study groups. Thereis a statistically significant difference in the percentage of improvement of modified RankinScale (mRS) , Communication Disability Scale (CDS) , and Cognitive Assessment of StrokePatients (CASP) scores between the study groups.

Conclusion: Our study concluded that patients received melatonin along with first-linetreatment has shown better efficacy in treating post recovery stroke patients when comparedwith patients received first-line treatment alone. Melatonin served as an excellentneuroprotectant in patients of acute ischemic stroke with improvement in the motor, speech andcognitive functions.

Keywords: Stroke, Melatonin, Modified rankinscale (mRS) , Communication disabilityscale (CDS) , Cognitive assessment of stroke patients (CASP)